PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Ten New Catalog Peptides - This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new catalog peptides and one new unusual amino acid
AnaSpec Introduces Ten New Catalog Peptides

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2008/01/02 - This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new catalog peptides and one new unusual amino acid.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MSL8; [Met256]-OVA (257-264)- Cat# 62573-5
Sequence: MSIINFEKL

MSL8; [Met256]-OVA (257-264)- Cat# 62573-1
Sequence: MSIINFEKL

OVA (257-264); amide- Cat# 62572-5
This octameric peptide is amino acids 257 to 264 amidated fragment of ovalbumin (OVA); a class I (Kb)-restricted peptide epitope of OVA; presented by the class I MHC molecule; H-2Kb.
Sequence: SIINFEKL-NH2

OVA (257-264); amide- Cat# 62572-1
This octameric peptide is amino acids 257 to 264 amidated fragment of ovalbumin (OVA); a class I (Kb)-restricted peptide epitope of OVA; presented by the class I MHC molecule; H-2Kb.
Sequence: SIINFEKL-NH2

OVA (323-339); amide- Cat# 62571-5
This peptide is amino acids 323 to 339 amidated fragment of ovalbumin (OVA); the H-2b-restricted OVA class II epitope. This peptide is recognized by many T cells because it contains multiple T cell epitopes. This OVA fragment contains a nested set of CD4+ T cell epitopes. OVA 323 to 339 can be presented by I-Ad in at least three binding registers. The residues 327 to 333 are critical for peptide binding to I-Ad
Sequence: ISQAVHAAHAEINEAGR-NH2

OVA (323-339); amide- Cat# 62571-1
This peptide is amino acids 323 to 339 amidated fragment of ovalbumin (OVA); the H-2b-restricted OVA class II epitope. This peptide is recognized by many T cells because it contains multiple T cell epitopes. This OVA fragment contains a nested set of CD4+ T cell epitopes. OVA 323 to 339 can be presented by I-Ad in at least three binding registers. The residues 327 to 333 are critical for peptide binding to I-Ad
Sequence: ISQAVHAAHAEINEAGR-NH2

HEL (46-61)- Cat# 60504-1
This peptide is amino acids 46 to 61 fragment of the hen egg lysozyme (HEL). Lysozyme is anti-bacterial enzyme found in high concentration in the egg white. HEL was used in in MHC related studies; and tested as a part of anti-microbial vaccines.
Sequence: NTDGSTDYGILQINSR

Vesicular Stomatitis Virus Nucleoprotein (52-59); VSV-8- Cat# 60785
This octapeptide is amino acids 52 to 59 fragment of the the vesicular stomatitis virus (VSV) nucleoprotein. VSV-8 is derived from the VSV nucleoprotein that is expressed in the cytosol of the infected cells. CTL response against VSV in H-2Kb mice is directed against this single VSV-8 immunodominant peptide. This 8 peptide forms complex with murine MHC class I molecule H-2Kb; which is similar to human HLA class I. This peptide was used in numerous MHC-binding studies and T-cell assays.
Sequence: RGYVYQGL

LEAP-1; Hepcidin; human- Cat# 61432
This 25 amino acid residues Liver-Expressed Antimicobial Peptide 1 (LEAP-1) is also known as hepcidin. LEAP-1 is a liver-specific peptide; but may be detected in the heart and brain at a lesser amount.
Sequence: DTHFPICIFCCGCCHRSKCGMCCKT (Disulfide bridges: 7-23; 10-22; 11-19; 13-14)

RNase S Complex Peptide- Cat# 62416
This peptide is a dead-end modified peptide from Ribonuclease S complex.
Sequence: Ac-KETAAAKFERQHMDSSTSA-NH2

Fmoc-Lys(4,5-dimethoxy-2-nitro-benzyloxycarbonyl)-OH- Cat# 62574-500/ Cat# 62574-1000
Light-sensitive Compatible with standard Fmoc protocols Nvoc group removed by photo-cleavage

About AnaSpec, Inc.

AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry. Established in 1993, AnaSpec's headquarters and manufacturing facilities are located in San Jose, CA.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Ten New Catalog Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Ping Yang 
1-408-452-5055 ping[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)